Legend Biotech has abruptly changed leadership, with CEO Ying Huang stepping down without a permanent replacement named. The board appointed Carvykti president Alan Bash as interim CEO, beginning July 23, with a company statement that a comprehensive search is underway. The shift comes as Legend continues to execute on commercial and clinical priorities centered on Carvykti, the Johnson & Johnson-partnered multiple myeloma CAR-T therapy. Industry watchers will likely focus on whether continuity at the commercial helm translates into steady momentum across clinical expansion and operational execution during the CEO transition window.